{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:55:49Z","timestamp":1792580149880,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.cgh.2021.09.028","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T06:37:33Z","timestamp":1632897453000},"page":"1059-1067.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn\u2019s Disease: ENTERPRISE Study"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7026-7099","authenticated-orcid":false,"given":"David A.","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Lasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashi","family":"Adsul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2021.09.028_bib1","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1136\/gutjnl-2013-306709","article-title":"A\u00a0global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn\u2019s disease","volume":"63","author":"Gecse","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2021.09.028_bib2","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/ecco-jcc\/jjw039","article-title":"Results of the Fifth Scientific Workshop of the ECCO [II]: clinical aspects of perianal fistulising Crohn\u2019s disease\u2014the unmet needs","volume":"10","author":"Gecse","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2021.09.028_bib3","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.3748\/wjg.v23.i23.4285","article-title":"Magnetic resonance imaging may predict deep remission in patients with perianal fistulizing Crohn\u2019s disease","volume":"23","author":"Thomassin","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.09.028_bib4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/gutjnl-2017-315503","article-title":"Developing a core outcome set for fistulising perianal Crohn\u2019s disease","volume":"68","author":"Sahnan","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2021.09.028_bib5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/ecco-jcc\/jjy019","article-title":"Efficacy of vedolizumab in fistulising Crohn\u2019s disease: exploratory analyses of data from GEMINI 2","volume":"12","author":"Feagan","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2021.09.028_bib6","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/ecco-jcc\/jjab026","article-title":"Endpoints for perianal Crohn\u2019s disease trials: past, present and future","volume":"15","author":"Caron","year":"2021","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2021.09.028_bib7","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease","volume":"340","author":"Present","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2021.09.028_bib8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s disease","volume":"350","author":"Sands","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2021.09.028_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2036.2010.04509.x","article-title":"Randomised clinical trial: certolizumab pegol for fistulas in Crohn\u2019s disease\u2014subgroup results from a placebo-controlled study","volume":"33","author":"Schreiber","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.09.028_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/MCG.0000000000000169","article-title":"Effectiveness of adalimumab in perianal fistulas in crohn's disease patients naive to anti-TNF therapy","volume":"49","author":"Castano-Milla","year":"2015","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2021.09.028_bib11","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/gutjnl-2013-304488","article-title":"Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn\u2019s disease: a randomised, double-blind, placebo controlled trial (ADAFI)","volume":"63","author":"Dewint","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2021.09.028_bib12","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/j.1365-2036.2004.02247.x","article-title":"Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn\u2019s disease with infliximab: a double-blind placebo-controlled study","volume":"20","author":"West","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.09.028_bib13","series-title":"Vedolizumab [summary of product characteristics]","year":"2019"},{"key":"10.1016\/j.cgh.2021.09.028_bib14","series-title":"Vedolizumab [prescribing information]","year":"2014"},{"key":"10.1016\/j.cgh.2021.09.028_bib15","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2021.09.028_bib16","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/apt.16060","article-title":"Long-term safety of vedolizumab for inflammatory bowel disease","volume":"52","author":"Loftus","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.09.028_bib17","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/j.cgh.2014.08.038","article-title":"Placebo response rate in clinical trials of fistulizing Crohn\u2019s disease: systematic review and meta-analysis","volume":"12","author":"Ford","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.09.028_bib18","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2021.09.028_bib19","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/apt.15665","article-title":"Vedolizumab for perianal Crohn\u2019s disease: a multicentre cohort study in 151 patients","volume":"51","author":"Chapuis-Biron","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.09.028_bib20","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/apt.12906","article-title":"Systematic review: the combined surgical and medical treatment of fistulising perianal Crohn\u2019s disease","volume":"40","author":"Yassin","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.09.028_bib21","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","article-title":"An overview of the mechanism of action of the monoclonal antibody vedolizumab","volume":"10","author":"Wyant","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2021.09.028_bib22","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/apt.15609","article-title":"A\u00a0clinical decision support tool may help to optimise vedolizumab therapy in Crohn\u2019s disease","volume":"51","author":"Dulai","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.09.028_bib23","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1093\/ecco-jcc\/jjy222.500","article-title":"Effects of IV vedolizumab on health-related quality of life and work productivity in patients with Crohn\u2019s disease: results from the Phase 3b VERSIFY trial (abstract)","volume":"13","author":"Danese","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2021.09.028_bib24","first-page":"412","article-title":"Long-term efficacy of vedolizumab for Crohn\u2019s disease","volume":"11","author":"Vermeire","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2021.09.028_bib25","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.09.028_bib26","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2021.09.028_bib27","article-title":"The VISIBLE 2 phase 3 study of efficacy and safety of vedolizumab SC for moderate-to-severe Crohn\u2019s disease (abstract)","volume":"158","author":"Vermeire","year":"2020","journal-title":"Gastroenterology"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356521010429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356521010429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:36:12Z","timestamp":1761543372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356521010429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1542356521010429"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2021.09.028","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn\u2019s Disease: ENTERPRISE Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2021.09.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}